Related Experiment Video
Updated: Mar 17, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
Prolonged Intermittent Chlorambucil Administration in B-Chronic Lymphocytic Leukemia: Experience from a Single
V A Boussiotis1, P G Panayiotidis1, G A Pangalis1
1a Hematology Unit. Lymphoma Clinic, University of Athens School of Medicine, Laikon General Hospital, Athens, Greece.
Prolonged intermittent chlorambucil (Chl) therapy for B-chronic lymphocytic leukemia (B-CLL) patients showed a significant increase in complete responders by 18 months. This extended treatment duration demonstrated comparable survival rates across all disease stages without increased toxicity.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Background:
- B-chronic lymphocytic leukemia (B-CLL) is a common lymphoid malignancy.
- Treatment strategies for B-CLL aim to improve patient survival and quality of life.
- The optimal duration of chlorambucil (Chl) therapy for B-CLL remains an area of investigation.
Purpose of the Study:
- To evaluate the efficacy of prolonged intermittent chlorambucil (Chl) administration compared to shorter durations in B-chronic lymphocytic leukemia (B-CLL) patients.
- To assess response rates and overall survival in B-CLL patients receiving extended Chl therapy.
- To determine the safety profile of prolonged Chl treatment in B-CLL.
Main Methods:
- A study involving 117 B-CLL patients scheduled for oral Chl (10 mg/daily for 10 days/month) up to 24 months.
- Analysis of 81 patients who completed at least 10 months of therapy, with a median follow-up of 40 months.
- Assessment of overall and complete response rates at 6 and 18 months, and survival analysis stratified by disease stage.
Main Results:
- Overall response rates at 6 and 18 months were similar (approx. 90%).
- A significant increase in complete responders was observed at 18 months (21%) compared to 6 months (7.4%) (p < 0.025).
- Median survival was 50 months for stage A, 51 months for stage B, and 33 months for stage C, with no statistically significant differences among stages. No significant toxicity or secondary malignancies were noted.
Conclusions:
- Eighteen months of intermittent chlorambucil (Chl) administration appears to achieve the highest response rates in B-chronic lymphocytic leukemia (B-CLL) patients.
- Prolonged Chl therapy demonstrated comparable overall survival across different disease stages (A, B, and C).
- Extended intermittent chlorambucil (Chl) treatment is a safe and effective option for B-CLL management.
More Related Videos
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...